AbbVie and REGENXBIO Initiate Phase 2b/3 Trial of Suravvec for Diabetic Retinopathy
Introduction of Innovative Suprachoroidal Delivery Route
The Phase 2b/3 (NAAVIGATE) trial of sura-vec (ABBV-RGX-314), a gene therapy for Diabetic Retinopathy co-developed by AbbVie and REGENXBIO, has commenced. This trial adopts a novel approach by administering the drug via the suprachoroidal space, a specialized route, instead of intravitreal injection. This differentiates it from conventional invasive intraocular injections and is strategically designed to maximize drug delivery efficiency and optimize drug distribution within the eye. Suprachoroidal administration is gaining attention as a next-generation ophthalmic treatment platform due to its ability to precisely target the retina while minimizing intraocular side effects.
Market Disruptive Potential of Single-Dose Gene Therapy
The core of this study is to validate the efficacy and long-term safety of sura-vec as a one-time gene therapy. Sura-vec utilizes an AAV8 vector to induce retinal cells to produce anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody fragments. This has the potential to significantly reduce the treatment burden for patients compared to existing standard treatments like Eylea and Lucentis, which require intravitreal injections every 1-3 months. If a single administration can maintain intraocular drug levels for life, it will undoubtedly be a game-changer, transforming the paradigm of chronic retinal disease management into a complete cure model.
Design and Risk Management of Phase 2b/3 NAAVIGATE Trial
The NAAVIGATE (protocol M23-415) trial, conducted in the United States and other countries, will evaluate the objective efficacy and safety of sura-vec through a randomized, sham-controlled design. The primary endpoint of this trial is the proportion of patients with a Diabetic Retinopathy Severity Score (DRSS) improvement of at least 2 steps at 1 year post-treatment. Notably, in the previous Phase 2 ALTITUDE trial, sura-vec demonstrated excellent results with no serious drug-related adverse events up to a 3-step dose, and no intraocular inflammation was observed, raising high expectations. With regulatory approval for Wet AMD expected soon, the successful and timely enrollment of patients in this Diabetic Retinopathy trial will be crucial for expanding the indications of sura-vec.
Proactive Early Treatment Strategy and Addressing Unmet Needs
This trial focuses on patients with moderate to severe non-proliferative diabetic retinopathy (NPDR) without macular edema. This strategy aims to proactively prevent disease progression and vision-threatening events by intervening at a stage before significant vision loss occurs. Existing standard treatments have been primarily applied to patients with advanced proliferative stages or macular edema, making the early targeting of patients a smart market entry strategy. Demonstrating early treatment efficacy will allow it to capture the largest patient pool in the global diabetic retinopathy treatment market, which is worth approximately $10 billion.
Sura-vec (ABBV-RGX-314), co-developed by AbbVie and REGENXBIO, is the first potential single-dose gene therapy candidate that can revolutionize the $10 billion diabetic retinopathy market by disrupting the repetitive dosing regimen. The initiation of the Phase 2b/3 trial (NAAVIGATE) represents a significant milestone that will reshape the market landscape by offering superior dosing convenience compared to existing standard treatments such as Eylea and Lucentis. In the short term, the initiation of the Phase 2b trial and the first patient enrollment will trigger a $100 million milestone payment from AbbVie to REGENXBIO, which will enhance the credibility and financial stability of the partnership. In the medium to long term, as the safety and platform utility of suprachoroidal space (SCS) injection technology are established, it is expected to raise the technological barrier in the field of ophthalmic gene therapy. Furthermore, based on its faster commercialization speed compared to competing pipelines such as 4D-150, it can maximize its exclusive commercial value in the global ophthalmic biologics market after 2026.
Source: ClinicalTrials.gov (api_ct)